Abstract

Purpose[18F]Fluoro-deoxy-glucose positron emission tomography/computed tomography (FDG-PET/CT) is used for response assessment during therapy in Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Clinicians report the scans visually using Deauville criteria. Improved performance in modern PET/CT scanners could allow for a reduction in scan time without compromising diagnostic image quality. Additionally, patient throughput can be increased with increasing cost-effectiveness. We investigated the effects of reducing scan time of response assessment FDG-PET/CT in HL and NHL patients on Deauville score (DS) and image quality.MethodsTwenty patients diagnosed with HL/NHL referred to a response assessment FDG-PET/CT were included. PET scans were performed in list-mode with an acquisition time of 120 s per bed position(s/bp). From PET list-mode data images with full acquisition time of 120 s/bp and shorter acquisition times (90, 60, 45, and 30 s/bp) were reconstructed. All images were assessed by two specialists and assigned a DS. We estimated the possible savings when reducing scan time using a simplified model based on assumed values/costs for our hospital.ResultsThere were no significant changes in the visually assessed DS when reducing scan time to 90 s/bp, 60 s/bp, 45 s/bp, and 30 s/bp. Image quality of 90 s/bp images were rated equal to 120 s/bp images. Coefficient of variance values for 120 s/bp and 90 s/bp images was significantly < 15%. The estimated annual savings to the hospital when reducing scan time was 8000-16,000 €/scanner.ConclusionAcquisition time can be reduced to 90 s/bp in response assessment FDG-PET/CT without compromising Deauville score or image quality. Reducing acquisition time can reduce costs to the clinic.

Highlights

  • Malignant lymphoma is the most common hematological malignancy in the world (Bray et al, 2018)

  • Acquisition time can be reduced to 90 s/bp in response assessment FDG-PET/CT without compromising Deauville score or image quality

  • The aim of this study is to investigate the effect of reducing scan time of response assessment PET/CT imaging performed on newly diagnosed patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL)

Read more

Summary

Introduction

Malignant lymphoma is the most common hematological malignancy in the world (Bray et al, 2018). In recent years, [18F]fluoro-deoxy-glucose positron emission tomography/computed tomography (FDG-PET/CT) has become the standard imaging procedure for initial staging and response assessment both during therapy and end of therapy in HL and FDGavid NHL (Cheson et al, 2014). FDG-avid areas are located anatomically by simultaneously performing a CT scan. Both HL and NHL are typically very FDG-avid (Weiler-Sagie et al, 2010). FDG-PET/CT has improved diagnostic accuracy in comparison to CT for staging in HL and NHL, with increased sensitivity for extranodal sites, and is recommended for staging (Barrington et al, 2014). Response assessment of lymphoma patients with an interim FDG-PET/CT is performed during treatment to ensure the effectiveness of treatment. Interim PET has proven to be a strong prognostic indicator in HL and NHL (Gallamini et al, 2007; Mikhaeel et al, 2005; Itti et al, 2013)

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call